Bath & Body Works Is Up for Sale.

Hey there, bargain hunter. An activist investor showed up at a candle-and-lotion retailer last night, and the question is not whether Barington Capital is right that Bath & Body Works is undervalued. The question is whether anyone will pay what it is worth.

Scoreboard

Bath & Body Works shares advanced about 2.3% in extended trading Thursday after reports that Barington Capital Group built a fresh position and is urging the board to explore a strategic sale. The stock was already down year-to-date before the news. GuruFocus rates BBWI as significantly undervalued, with its GF Value estimate around the low-$30s versus a recent high-teens share price, implying a discount on the order of the mid-40% range.

Valuation gaps of that magnitude are rare in consumer retail, and they tend to persist longest when the market is skeptical that a brand’s margins are durable. That skepticism is not unique to Bath & Body Works — Inditex’s premium valuation and what its gross margin tells investors about pricing power in apparel retail offers a useful contrast, showing how the market prices a consumer brand when margin durability is not in question.

What Barington Actually Said

James Mitarotonda disclosed a stake of approximately one million shares in an interview with Bloomberg, signaling a renewed intervention at the Columbus, Ohio-based company he previously targeted in 2019 under its former corporate identity, L Brands. His core argument: the company is undervalued, has been hampered by unstable management, and should retain advisers to shop itself.

Barington is also seeking board representation and, according to Bloomberg, intends to issue a letter to directors in the coming weeks. The activist also wants Bath & Body Works to improve shareholder returns through actions like share repurchases. The board has not responded publicly.

The Business Behind the Candles

Bath & Body Works sells home fragrance, body care, soaps, and sanitizers under its own brand and the White Barn label. It also runs e-commerce in the U.S. and Canada and sells internationally through partner-operated stores and other arrangements. The model is high-margin, repeat-purchase, and intensely seasonal, with the holiday quarter doing the heavy lifting.

Total net sales were $7,291 million in fiscal 2025, essentially flat year-over-year. Operating income came in at $1,126 million, down from 2024, with the operating margin contracting to 15.4% from 17.3%. That is still about 15 cents of operating income on every dollar of sales, a figure most mall retailers cannot touch.

Data Section

• FY2025 net sales: $7,291 million
• FY2025 operating income: $1,126 million (15.4% margin)
• FY2026 sales guidance (as of late August 2026): down 2.5% to 4% vs. fiscal 2025
• FY2026 EPS guidance (as of late August 2026): $3.13 to $3.33 per diluted share
• Cost savings plan: $250 million targeted over two years
• Dividend yield: roughly mid-4% range at recent high-teens prices, with a $0.80 annual dividend

Is It Cheap?

In the high teens, BBWI trades at roughly 5 to 6x its guided EPS range midpoint. That is compressed even for a specialty retailer facing a sales reset. Mitarotonda told Bloomberg that the company’s market position, brand strength, and cash generation should attract buyer interest, including from private equity. Private equity buyers typically pay 8 to 10x EBITDA for branded consumer businesses with durable cash flow. If the business can stabilize and keep generating substantial free cash flow, even a conservative multiple suggests meaningful upside to where the stock sits today.

In late August, Reuters reported that Bath & Body Works forecast a wider-than-expected decline in current-quarter sales, citing weak store traffic and broader weakness in mall traffic. That is the bear case in a single sentence.

Bull / Base / Bear

Bull: A private equity buyer or strategic acquirer pays 9x EBITDA. The brand’s pricing power and loyalty economics justify the premium. Mitarotonda wins.

Base: No deal materializes. Current CEO Daniel Heaf, appointed in May 2025 after a career at Nike, pushes a modernization plan that includes marketplace expansion (including Amazon) and tighter execution, while Barington’s pressure accelerates capital returns and cost actions. The stock re-rates modestly if results stop sliding.

Bear: Mall traffic continues to erode. Sales declines deepen past guidance. Debt on the balance sheet limits flexibility. Barington’s campaign stalls with no board seats secured.

Debt constraining strategic flexibility is a recurring theme in consumer brand investing right now, and it is worth understanding how the market is pricing that risk elsewhere. Wella’s IPO breakdown: strong brand margins weighed against $2.3 billion in KKR leverage walks through a comparable situation where attractive brand economics are complicated by a heavily loaded balance sheet — a useful frame for thinking about how much debt a buyer would be willing to absorb in a Bath & Body Works deal.

Action Plan

This is an event-driven situation with a real fundamental floor. The cash flow provides a margin of safety at current prices, but it is not a bond, and the traffic risk is real. Scale in at or below the high teens, size it as a speculative activist position, and watch for the board letter Barington says is coming in the next few weeks. A seat at the table changes the math. Trim aggressively on a sharp pop if no formal process is confirmed.

The broader question of how to value a consumer retail business when its identity is shifting — whether toward tech, marketplace, or modernization — is one the market is wrestling with across the sector. Walmart’s valuation debate: whether its grocery roots or its technology ambitions should set the multiple explores how a retailer’s strategic repositioning can dramatically change the lens investors use to price the stock — relevant context as Bath & Body Works pursues its own marketplace expansion under CEO Daniel Heaf.

Cheap Investor Checklist

• Barington board letter published and seats secured: yes/no
• Company retains financial advisers for strategic review: yes/no
• Operating margin holds near mid-teens in FY2026: yes/no
• Comparable sales trend improves versus guidance: yes/no
• Share repurchase program initiated or expanded: yes/no
• Debt reduction continues on schedule: yes/no
• PE or strategic buyer confirms interest publicly: yes/no

Bottom Line

If Barington secures board influence and a sale process opens, this stock has a credible path to materially higher prices. If the board stonewalls and traffic trends worsen, the dividend and cash flow help, but they do not make the equity risk-free. The activist is not just loud. The numbers give the argument real weight. Position accordingly, and do not bet the portfolio on a deal closing.